G-CSF (filgrastim)-stimulated whole blood kept unprocessed at 4°C does support a BEAM-like regimen in bad-risk lymphoma

Bone Marrow Transplantation

Volumn 18, Issue 2, 1996, Pages 427-431

  Ossenkoppele, G J ^a   Schuurhuis, G J ^a   Jonkhoff, A R ^a   Drager A M ^a   Westra, G ^a   Oberink, J W ^a   Legdeur, M C J C ^a   De Kreuk, A M ^a   Zweegman, S ^a   Huijgens, P C ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

G CSF; NHL; Stem cell transplantation

Indexed keywords

ANTIBIOTIC AGENT; CARMUSTINE; CD34 ANTIGEN; CYTARABINE; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; METHOTREXATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ARTICLE; BLOOD STORAGE; CLINICAL ARTICLE; FEMALE; HEALTH CARE COST; HOSPITALIZATION; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE DIFFERENTIAL COUNT; LYMPHOMA; MALE; NEUTROPHIL; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION;

ADULT; ANTIGENS, CD34; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; COLD; COMBINED MODALITY THERAPY; CYTARABINE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA; MALE; MELPHALAN; MIDDLE AGED; PODOPHYLLOTOXIN;

EID: 9444252248     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Pettengell R, Morgenstern GR, Woll PJ et al. Peripheral blood progenitor transplantation in lymphoma and leukemia using a single leucapheresis. Blood 1993; 82: 3770-3777.
2. Lowry P, Tabbara IA. Peripheral hematopoietic stem cell transplantation: current concepts. Exp Hematol 1992; 20: 937-942.
3. Faucher C, le Corroller AG, Blaise D et al. Comparison of G-CSF primed peripheral blood progenitor cells and bone marrow auto transplantation: clinical assessment and cost-effectiveness. Bone Marrow Transplant 1994; 14: 895-901.
4. Ossenkoppele GJ, Jonkhoff AR, Huijgens PC et al. Peripheral blood progenitors mobilised by G-CSF (filgrastim) and reinfused as unprocessed whole blood shorten the pancytopenic period following high dose melphalan in multiple myeloma. Bone Marrow Transplant 1994; 13: 37-41.
5. Huijgens PC, Ossenkoppele GJ, Weyers TF et al. Imipenemcilastatin for emperical therapy in neutropenic patients with fever: an open study in patients with hematological malignancies. Eur J Haematol 1991; 46: 42-46.
6. Uyl-Groot de CA, Ossenkoppele GJ, Riet van AAPM, Rutten FFH. The costs of peripheral blood progenitor cell reinfusion mobilised by granulocyte colony stimulating factor following high dose melphalan as compared with conventional therapy in multiple myeloma. Eur J Cancer 1994; 30: 457-459.
7. Pettengell R, Woll PJ, Thatcher N et al. Multicyclic, dose-intensive chemotherapy supported by sequential reinfusion of hematopoietic progenitors in whole blood. J Clin Oncol 1995; 13: 148-156.
8. Pettengell R, Woll PJ, O'Connor DA et al. Viability of haematopoietic progenitors from whole blood, bone marrow and leukapheresis product: effects of storage media, temperature and time. Bone Marrow Transplant 1994; 14: 703-709.
9. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. New Engl J Med 1995; 333: 1540-1550.
10. de Kreuk AM, Ossenkoppele GJ, Meijer CJLM, Huijgens PC. Prognostic factors for survival of non-Hodgkin's lymphoma patients treated with high dose chemotherapy and autologous bone marrow transplantation. Bone Marrow Transplant 1996; 17: 963-971.
11. Jones HM, Jones SA, Watts MJ et al. Development of a simplified single apheresis approach for peripheral blood progenitor cell transplantation in previously treated patients with lymphoma. J Clin Oncol 1994; 12: 1693-1702.
12. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas. Summary and description of a working formulation for clinical usage. Cancer 1982; 49: 2112-2129.